You are here
Abbvie drops by a record as US$63b mega deal for Botox maker fails to end doubts
[BOSTON] AbbVie Inc. has agreed to pay US$63 billion for rival drugmaker Allergan Plc, the latest merger in an industry where some of the biggest companies have been willing to pay a big premium to resolve questions about their growth prospects.
The price tag caused heartburn on Wall Street, and AbbVie had its worst day of trading since it was spun off from former parent Abbott Laboratories. The stock closed down 16 per cent to US$65.70 in New York.
Allergan shares finished the day up 25 per cent to US$162.43. AbbVie will pay US$188.24 a share in cash and stock, according to a statement, a 45 per cent premium to Allergan's closing price on Monday.
"Allergan, with its well-known Botox, is being used to smooth the wrinkles this time not of a face but of a company," said David Maris, an analyst with Wells Fargo.
"While this is a good alternative for Allergan versus the current share price, we are not convinced that this is a better long-term alternative for shareholders."
The proposed takeover doesn't give AbbVie a pipeline full of potential blockbuster drugs, but it buys the company time to develop more. Allergan provides AbbVie with a set of products big enough to diversify its revenue from Humira, the rheumatoid arthritis injection that is the world's biggest-selling drug worldwide, with about US$20 billion in sales last year. Allergan, which is heavily reliant on the wrinkle reducer Botox, will get a profitable exit for shareholders after a four-year slide.
While they use cost savings from the deal to shore up profits, the companies will still be under pressure to show investors they can come up with the next big thing.
AbbVie may be nearing the limits of how far it can boost Humira's price as cheaper competitors come to market, a problem Allergan is already grappling with as more alternatives to Botox emerge.
The companies have developed several potentially promising medicines for a range of diseases, though so far none have convinced investors that they can attract the vast pool of patients that take medications like Humira.
On a conference call announcing the deal, AbbVie chief executive officer Richard Gonzalez, who will lead the combined company, said the transaction should ease concerns about future competition to Humira, adding that the drug is lucrative enough to bankroll the purchase of its eventual successor.
"This is a transformation transaction that provides important strategic benefits for both AbbVie and Allergan," Mr Gonzalez said. "This will have a profound impact on AbbVie's overall growth story."
Mr Gonzalez said on the call with investors that the transaction "isn't highly dependent on pipeline".
One drug considered to be a contender to replace some of Humira's sales over the long term is AbbVie's Skyrizi, a new psoriasis treatment that many patients may find more convenient than Humira, as it needs to be injected less frequently.
"Patients love Skyrizi, it's a big contender," said Mark Lebwohl, the Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York. "It's four shots a year and appears to be incredibly effective. AbbVie already knows how to sell this drug."
The drop in North Chicago, Illinois-based AbbVie's shares Tuesday also reflects investors' concerns over activist opposition and regulatory scrutiny.
Earlier this year, Bristol-Myers Squibb faced opposition from some top investors to abandon its US$74 billion acquisition of Celgene. The transaction eventually won the backing of a majority of shareholders, but Bristol-Myers shares are still trading well below their pre-deal value.
On Monday, Bristol-Myers said that it had agreed to divest one of Celgene's top products, the psoriasis pill Otezla, in order to appease regulators at the U.S. Federal Trade Commission.
While there are few major areas of overlap between Allergan and AbbVie, the deal is almost certain to get a careful look from regulators. The company does plan to divest two Allergan drugs, IL-23 and Zenpep, to ensure the deal passes muster, Mr Gonzalez said.
Still, AbbVie's acquisition is evidence that the world's biggest drugmakers believe bigger is better. Along with Bristol-Myers's deal for Celgene, Japan's Takeda Pharmaceutical earlier this year completed a US$62 billion takeover of Shire.
A combined AbbVie and Allergan will have sales of about US$48 billion, the companies said in a statement, making it one of the biggest in the industry.
BACK TO THE US
The deal will return Allergan to the US, at least for tax purposes. While the company is run from New Jersey, it moved its domicile to Dublin in 2015 via another merger, partly to take advantage of lower corporate rates abroad. The 2017 US tax overhaul cut corporate levies to 21 per cent from 35 per cent, which reduced incentives for companies to relocate overseas.
AbbVie currently pays far less in tax than that, however, and has said it will have an effective rate of 9 per cent this year. It has projected its effective rate will rise to 13 per cent.
Allergan CEO Brent Saunders had spent months turning over plans for the drugmaker's future as its stock price dropped from a 2015 peak of almost US$340. Those options included selling off the company's gastrointestinal drugs or women's health unit, which would have left it more focused on its profitable medical aesthetics line that includes Botox.
AbbVie said it expects at least US$2 billion in annual pretax synergies and other cost reductions in year three of the deal.
Allergan holders will receive 0.8660 AbbVie shares and US$120.30 in cash for each share they hold. AbbVie will take on Allergan's debt, which totaled about US$24 billion at the end of the first quarter.
Two Allergan directors, including Mr Saunders, will join AbbVie's board after the purchase is completed, according to the statement. Mr Gonzalez said on the call that he intends to stay with the company at least through Humira's loss of exclusivity in the US.
The deal is expected to close in early 2020, the companies said.
Morgan Stanley & Co. acted as AbbVie's financial adviser and Kirkland & Ellis LLP and McCann FitzGerald were legal advisers. JPMorgan Chase & Co. was AbbVie's financial adviser, and Wachtell, Lipton, Rosen & Katz and Arthur Cox gave legal advice. PJT Partners Inc. was a co-financial adviser to AbbVie.